0 оценок0% нашли этот документ полезным (0 голосов)
160 просмотров1 страница
This document summarizes the pharmacological and pharmacokinetic properties of beta receptor blocking agents. It describes first, second, and third generation beta blockers, comparing their membrane stabilizing activity, intrinsic agonist activity, lipid solubility, oral bioavailability, plasma half-life, and protein binding. Third generation beta blockers are distinguished by additional cardiovascular actions including nitric oxide production, beta2 receptor agonism, alpha1 receptor antagonism, calcium entry blockade, and potassium channel opening. The document also notes pharmacological differences between agents and their specific indications for conditions like cardiac arrhythmia, congestive heart failure, glaucoma, myocardial infarction, and migraine prophylaxis.
This document summarizes the pharmacological and pharmacokinetic properties of beta receptor blocking agents. It describes first, second, and third generation beta blockers, comparing their membrane stabilizing activity, intrinsic agonist activity, lipid solubility, oral bioavailability, plasma half-life, and protein binding. Third generation beta blockers are distinguished by additional cardiovascular actions including nitric oxide production, beta2 receptor agonism, alpha1 receptor antagonism, calcium entry blockade, and potassium channel opening. The document also notes pharmacological differences between agents and their specific indications for conditions like cardiac arrhythmia, congestive heart failure, glaucoma, myocardial infarction, and migraine prophylaxis.
Авторское право:
Attribution Non-Commercial (BY-NC)
Доступные форматы
Скачайте в формате DOC, PDF, TXT или читайте онлайн в Scribd
This document summarizes the pharmacological and pharmacokinetic properties of beta receptor blocking agents. It describes first, second, and third generation beta blockers, comparing their membrane stabilizing activity, intrinsic agonist activity, lipid solubility, oral bioavailability, plasma half-life, and protein binding. Third generation beta blockers are distinguished by additional cardiovascular actions including nitric oxide production, beta2 receptor agonism, alpha1 receptor antagonism, calcium entry blockade, and potassium channel opening. The document also notes pharmacological differences between agents and their specific indications for conditions like cardiac arrhythmia, congestive heart failure, glaucoma, myocardial infarction, and migraine prophylaxis.
Авторское право:
Attribution Non-Commercial (BY-NC)
Доступные форматы
Скачайте в формате DOC, PDF, TXT или читайте онлайн в Scribd